<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times" color="#000000"/>
	<fontspec id="font1" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font3" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font6" size="10" family="Times" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="11" family="Helvetica,Bold" color="#000000"/>
<text top="42" left="243" width="126" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">PRACTICE GUIDELINE SERIES</text>
<text top="765" left="226" width="161" height="9" font="font1" id="p1_t2" reading_order_no="119" segment_no="18" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="755" left="57" width="20" height="11" font="font5" id="p1_t3" reading_order_no="118" segment_no="13" tag_type="text">106<i>URRENT</i></text>
<text top="84" left="55" width="239" height="9" font="font6" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">chemotherapy-refractory CLL . That conclusion is<i> O</i></text>
<text top="95" left="55" width="239" height="9" font="font6" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">based on response data from single-arm studies that<i>NCOLOGY</i></text>
<text top="105" left="55" width="239" height="9" font="font6" id="p1_t6" reading_order_no="3" segment_no="1" tag_type="text">report a PR in approximately one third of patients (rec-<i>—</i></text>
<text top="117" left="55" width="239" height="9" font="font6" id="p1_t7" reading_order_no="4" segment_no="1" tag_type="text">ognizing that CR are uncommon). From the perspec-<i>V</i></text>
<text top="128" left="55" width="239" height="9" font="font6" id="p1_t8" reading_order_no="5" segment_no="1" tag_type="text">tive of drug or multi-agent regimen development,<i>OLUME</i></text>
<text top="138" left="55" width="239" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="1" tag_type="text">these data are extremely promising and warrant fur-<i> 14, N</i></text>
<text top="150" left="55" width="132" height="9" font="font6" id="p1_t10" reading_order_no="7" segment_no="1" tag_type="text">ther testing of alemtuzumab.<i>UMBER</i></text>
<text top="161" left="73" width="221" height="9" font="font6" id="p1_t11" reading_order_no="8" segment_no="3" tag_type="text">In their deliberations, the DSG cited these factors<i> 3</i></text>
<text top="171" left="55" width="239" height="9" font="font6" id="p1_t12" reading_order_no="9" segment_no="3" tag_type="text">as leading to the current recommendation on<b>106</b></text>
<text top="183" left="55" width="65" height="9" font="font6" id="p1_t13" reading_order_no="10" segment_no="3" tag_type="text">alemtuzumab:</text>
<text top="204" left="55" width="4" height="9" font="font6" id="p1_t14" reading_order_no="11" segment_no="4" tag_type="list">•</text>
<text top="204" left="73" width="191" height="9" font="font6" id="p1_t15" reading_order_no="12" segment_no="4" tag_type="list">Lack of data from properly designed RCT s</text>
<text top="216" left="55" width="4" height="9" font="font6" id="p1_t16" reading_order_no="13" segment_no="5" tag_type="list">•</text>
<text top="216" left="73" width="221" height="9" font="font6" id="p1_t17" reading_order_no="14" segment_no="5" tag_type="list">A paucity of data suggesting improved response</text>
<text top="227" left="73" width="221" height="9" font="font6" id="p1_t18" reading_order_no="15" segment_no="5" tag_type="list">duration, quality of life, or improved overall sur-</text>
<text top="237" left="73" width="221" height="9" font="font6" id="p1_t19" reading_order_no="16" segment_no="5" tag_type="list">vival when alemtuzumab is compared with alter-</text>
<text top="249" left="73" width="129" height="9" font="font6" id="p1_t20" reading_order_no="17" segment_no="5" tag_type="list">native treatment approaches</text>
<text top="260" left="55" width="4" height="9" font="font6" id="p1_t21" reading_order_no="18" segment_no="7" tag_type="list">•</text>
<text top="260" left="73" width="221" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="7" tag_type="list">Significant potential toxicity, particularly infec-</text>
<text top="270" left="73" width="166" height="9" font="font6" id="p1_t23" reading_order_no="20" segment_no="7" tag_type="list">tion-related morbidity and mortality</text>
<text top="293" left="73" width="221" height="9" font="font6" id="p1_t24" reading_order_no="21" segment_no="8" tag_type="text">Given the anticipated toxicity, data from RCT s</text>
<text top="303" left="55" width="239" height="9" font="font6" id="p1_t25" reading_order_no="22" segment_no="8" tag_type="text">demonstrating improvement in clinically meaning-</text>
<text top="315" left="55" width="239" height="9" font="font6" id="p1_t26" reading_order_no="23" segment_no="8" tag_type="text">ful outcome measures—for example, time to progres-</text>
<text top="326" left="55" width="239" height="9" font="font6" id="p1_t27" reading_order_no="24" segment_no="8" tag_type="text">sion, quality of life, or overall survival—are required</text>
<text top="336" left="55" width="239" height="9" font="font6" id="p1_t28" reading_order_no="25" segment_no="8" tag_type="text">before recommendations permitting the routine use</text>
<text top="348" left="55" width="239" height="9" font="font6" id="p1_t29" reading_order_no="26" segment_no="8" tag_type="text">of alemtuzumab in this patient population can be</text>
<text top="359" left="55" width="28" height="9" font="font6" id="p1_t30" reading_order_no="27" segment_no="8" tag_type="text">made.</text>
<text top="368" left="73" width="221" height="10" font="font6" id="p1_t31" reading_order_no="28" segment_no="10" tag_type="text">The practice guidelines published by ESMO 29 and</text>
<text top="379" left="55" width="239" height="11" font="font6" id="p1_t32" reading_order_no="29" segment_no="10" tag_type="text">the U.K. CLL Forum 30 made recommendations re-</text>
<text top="392" left="55" width="239" height="9" font="font6" id="p1_t33" reading_order_no="30" segment_no="10" tag_type="text">garding the use of alemtuzumab in previously treated</text>
<text top="402" left="55" width="239" height="9" font="font6" id="p1_t34" reading_order_no="31" segment_no="10" tag_type="text">patients. The ESMO guideline recommends alem-</text>
<text top="414" left="55" width="239" height="9" font="font6" id="p1_t35" reading_order_no="32" segment_no="10" tag_type="text">tuzumab as an option for patients with refractory dis-</text>
<text top="425" left="55" width="239" height="9" font="font6" id="p1_t36" reading_order_no="33" segment_no="10" tag_type="text">ease following first-line therapy, based on the</text>
<text top="435" left="55" width="239" height="9" font="font6" id="p1_t37" reading_order_no="34" segment_no="10" tag_type="text">lowest-level evidence ( ASCO level V : small case-series).</text>
<text top="447" left="55" width="239" height="9" font="font6" id="p1_t38" reading_order_no="35" segment_no="10" tag_type="text">In addition, the U.K. CLL Forum guideline recom-</text>
<text top="458" left="55" width="239" height="9" font="font6" id="p1_t39" reading_order_no="36" segment_no="10" tag_type="text">mends alemtuzumab for use in patients without bulky</text>
<text top="468" left="55" width="239" height="9" font="font6" id="p1_t40" reading_order_no="37" segment_no="10" tag_type="text">lymphadenopathy (&lt;5 cm) who have been previously</text>
<text top="480" left="55" width="239" height="9" font="font6" id="p1_t41" reading_order_no="38" segment_no="10" tag_type="text">treated with alkylating agents and who are refractory</text>
<text top="491" left="55" width="239" height="9" font="font6" id="p1_t42" reading_order_no="39" segment_no="10" tag_type="text">to fludarabine. The evidence informing the U.K. CLL</text>
<text top="501" left="55" width="239" height="9" font="font6" id="p1_t43" reading_order_no="40" segment_no="10" tag_type="text">Forum recommendation was similar to the evidence</text>
<text top="513" left="55" width="239" height="9" font="font6" id="p1_t44" reading_order_no="41" segment_no="10" tag_type="text">contained in the present report and comprised data</text>
<text top="524" left="55" width="210" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="10" tag_type="text">from a smaller selection of single-arm studies.</text>
<text top="534" left="73" width="221" height="9" font="font6" id="p1_t46" reading_order_no="43" segment_no="12" tag_type="text">The German CLL Study Group determined that</text>
<text top="546" left="55" width="239" height="9" font="font6" id="p1_t47" reading_order_no="44" segment_no="12" tag_type="text">definitive recommendations could not be made re-</text>
<text top="557" left="55" width="239" height="9" font="font6" id="p1_t48" reading_order_no="45" segment_no="12" tag_type="text">garding alemtuzumab use and indicated that further</text>
<text top="566" left="55" width="209" height="10" font="font6" id="p1_t49" reading_order_no="46" segment_no="12" tag_type="text">testing in clinical trials would be preferred 31 .</text>
<text top="577" left="73" width="221" height="11" font="font6" id="p1_t50" reading_order_no="47" segment_no="14" tag_type="text">Keating et al. 26 did not make explicit recommen-</text>
<text top="590" left="55" width="239" height="9" font="font6" id="p1_t51" reading_order_no="48" segment_no="14" tag_type="text">dations regarding the appropriateness of alemtuzumab</text>
<text top="600" left="55" width="239" height="9" font="font6" id="p1_t52" reading_order_no="49" segment_no="14" tag_type="text">use in CLL patients, but implied that alemtuzumab is</text>
<text top="612" left="55" width="239" height="9" font="font6" id="p1_t53" reading_order_no="50" segment_no="14" tag_type="text">appropriate in fludarabine-refractory patients. Those</text>
<text top="623" left="55" width="239" height="9" font="font6" id="p1_t54" reading_order_no="51" segment_no="14" tag_type="text">authors also stated that advanced age should not be a</text>
<text top="633" left="55" width="173" height="9" font="font6" id="p1_t55" reading_order_no="52" segment_no="14" tag_type="text">contraindication to alemtuzumab use.</text>
<text top="645" left="73" width="221" height="9" font="font6" id="p1_t56" reading_order_no="53" segment_no="15" tag_type="text">The Hematology DSG considered the above rec-</text>
<text top="656" left="55" width="239" height="9" font="font6" id="p1_t57" reading_order_no="54" segment_no="15" tag_type="text">ommendations to be based on low levels of evidence</text>
<text top="666" left="55" width="239" height="9" font="font6" id="p1_t58" reading_order_no="55" segment_no="15" tag_type="text">and, initially, DSG members were not convinced that</text>
<text top="678" left="55" width="239" height="9" font="font6" id="p1_t59" reading_order_no="56" segment_no="15" tag_type="text">these recommendations could inform best clinical</text>
<text top="689" left="55" width="239" height="9" font="font6" id="p1_t60" reading_order_no="57" segment_no="15" tag_type="text">practice. Instead, the DSG initially concluded that po-</text>
<text top="699" left="55" width="239" height="9" font="font6" id="p1_t61" reading_order_no="58" segment_no="15" tag_type="text">tential benefits (response rates in a minority of pa-</text>
<text top="711" left="55" width="239" height="9" font="font6" id="p1_t62" reading_order_no="59" segment_no="15" tag_type="text">tients; uncertain benefit in terms of response duration,</text>
<text top="722" left="55" width="239" height="9" font="font6" id="p1_t63" reading_order_no="60" segment_no="15" tag_type="text">overall survival, and quality of life) were offset by</text>
<text top="84" left="318" width="239" height="9" font="font6" id="p1_t64" reading_order_no="61" segment_no="2" tag_type="text">the potential for significant toxicity. Therefore, an</text>
<text top="95" left="318" width="239" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="2" tag_type="text">initial recommendation was developed to indicate that</text>
<text top="105" left="318" width="239" height="9" font="font6" id="p1_t66" reading_order_no="63" segment_no="2" tag_type="text">the data were insufficient to support the routine use</text>
<text top="117" left="318" width="238" height="9" font="font6" id="p1_t67" reading_order_no="64" segment_no="2" tag_type="text">of alemtuzumab in patients with CLL . The DSG ac-</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t68" reading_order_no="65" segment_no="2" tag_type="text">knowledged the potential controversy that could re-</text>
<text top="138" left="318" width="239" height="9" font="font6" id="p1_t69" reading_order_no="66" segment_no="2" tag_type="text">sult from issuing a “non-permissive” recommendation</text>
<text top="150" left="318" width="239" height="9" font="font6" id="p1_t70" reading_order_no="67" segment_no="2" tag_type="text">regarding alemtuzumab use and the potential impli-</text>
<text top="161" left="318" width="239" height="9" font="font6" id="p1_t71" reading_order_no="68" segment_no="2" tag_type="text">cations that such a recommendation might have for</text>
<text top="171" left="318" width="239" height="9" font="font6" id="p1_t72" reading_order_no="69" segment_no="2" tag_type="text">drug availability. The DSG was aware that its recom-</text>
<text top="183" left="318" width="239" height="9" font="font6" id="p1_t73" reading_order_no="70" segment_no="2" tag_type="text">mendations differed from those of other existing prac-</text>
<text top="194" left="318" width="239" height="9" font="font6" id="p1_t74" reading_order_no="71" segment_no="2" tag_type="text">tice recommendations, including those published by</text>
<text top="204" left="318" width="145" height="9" font="font6" id="p1_t75" reading_order_no="72" segment_no="2" tag_type="text">ESMO and the U.K. CLL Forum.</text>
<text top="216" left="336" width="220" height="9" font="font6" id="p1_t76" reading_order_no="73" segment_no="6" tag_type="text">The DSG was also aware that, within the response</text>
<text top="227" left="318" width="239" height="9" font="font6" id="p1_t77" reading_order_no="74" segment_no="6" tag_type="text">data described in the literature reviewed, responses</text>
<text top="237" left="318" width="239" height="9" font="font6" id="p1_t78" reading_order_no="75" segment_no="6" tag_type="text">reached a magnitude that reporting authors—and</text>
<text top="249" left="318" width="239" height="9" font="font6" id="p1_t79" reading_order_no="76" segment_no="6" tag_type="text">members of the DSG —considered to be clinically im-</text>
<text top="260" left="318" width="239" height="9" font="font6" id="p1_t80" reading_order_no="77" segment_no="6" tag_type="text">portant. Although the precise frequency of the re-</text>
<text top="270" left="318" width="239" height="9" font="font6" id="p1_t81" reading_order_no="78" segment_no="6" tag_type="text">sponses was uncertain (and the best estimate was that</text>
<text top="282" left="318" width="239" height="9" font="font6" id="p1_t82" reading_order_no="79" segment_no="6" tag_type="text">they would be infrequent), the DSG acknowledged that</text>
<text top="293" left="318" width="239" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="6" tag_type="text">an opportunity for such a response, even with sub-</text>
<text top="303" left="318" width="239" height="9" font="font6" id="p1_t84" reading_order_no="81" segment_no="6" tag_type="text">stantial risks of toxicity, may be highly desired by<i>et al.</i></text>
<text top="315" left="318" width="239" height="9" font="font6" id="p1_t85" reading_order_no="82" segment_no="6" tag_type="text">some patients. The DSG attempted to reflect this sen-</text>
<text top="326" left="318" width="239" height="9" font="font6" id="p1_t86" reading_order_no="83" segment_no="6" tag_type="text">timent by indicating that, after balancing the benefits</text>
<text top="336" left="318" width="239" height="9" font="font6" id="p1_t87" reading_order_no="84" segment_no="6" tag_type="text">and risks of treatment, certain patients may wish to</text>
<text top="348" left="318" width="120" height="9" font="font6" id="p1_t88" reading_order_no="85" segment_no="6" tag_type="text">consider a trial of therapy.</text>
<text top="359" left="336" width="220" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">The DSG members had concerns with issuing an</text>
<text top="369" left="318" width="239" height="9" font="font6" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">unclear and potentially conflicting set of recommen-</text>
<text top="381" left="318" width="239" height="9" font="font6" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">dations, but they initially considered this option to</text>
<text top="392" left="318" width="239" height="9" font="font6" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">represent the best available alternative, and they there-</text>
<text top="402" left="318" width="239" height="9" font="font6" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">fore offered this guidance: For patients with CLL , the</text>
<text top="414" left="318" width="239" height="9" font="font6" id="p1_t94" reading_order_no="91" segment_no="9" tag_type="text">evidence is insufficient to recommend the use of</text>
<text top="425" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="92" segment_no="9" tag_type="text">alemtuzumab outside of clinical trials. The DSG rec-</text>
<text top="435" left="318" width="239" height="9" font="font6" id="p1_t96" reading_order_no="93" segment_no="9" tag_type="text">ognizes that, in highly selected cases, after thorough</text>
<text top="447" left="318" width="239" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="9" tag_type="text">consideration of the risks and benefits, a trial of</text>
<text top="458" left="318" width="161" height="9" font="font6" id="p1_t98" reading_order_no="95" segment_no="9" tag_type="text">alemtuzumab might be considered.</text>
<text top="468" left="336" width="221" height="9" font="font6" id="p1_t99" reading_order_no="96" segment_no="11" tag_type="text">Section 6 details the subsequent practitioner feed-</text>
<text top="480" left="318" width="239" height="9" font="font6" id="p1_t100" reading_order_no="97" segment_no="11" tag_type="text">back, and it notes that responding clinicians were</text>
<text top="491" left="318" width="239" height="9" font="font6" id="p1_t101" reading_order_no="98" segment_no="11" tag_type="text">generally in agreement with the synthesis and inter-</text>
<text top="501" left="318" width="239" height="9" font="font6" id="p1_t102" reading_order_no="99" segment_no="11" tag_type="text">pretation of the available literature and the resulting</text>
<text top="513" left="318" width="239" height="9" font="font6" id="p1_t103" reading_order_no="100" segment_no="11" tag_type="text">recommendations. However, a small number of re-</text>
<text top="524" left="318" width="239" height="9" font="font6" id="p1_t104" reading_order_no="101" segment_no="11" tag_type="text">spondents commented on the lack of clarity associ-</text>
<text top="534" left="318" width="239" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="11" tag_type="text">ated with the recommendations. As a result, the DSG</text>
<text top="546" left="318" width="239" height="9" font="font6" id="p1_t106" reading_order_no="103" segment_no="11" tag_type="text">members continued the consensus process in an ef-</text>
<text top="557" left="318" width="239" height="9" font="font6" id="p1_t107" reading_order_no="104" segment_no="11" tag_type="text">fort to develop a clearer statement, and the DSG sub-</text>
<text top="567" left="318" width="239" height="9" font="font6" id="p1_t108" reading_order_no="105" segment_no="11" tag_type="text">sequently issued a new set of recommendations. The</text>
<text top="579" left="318" width="239" height="9" font="font6" id="p1_t109" reading_order_no="106" segment_no="11" tag_type="text">redeveloped recommendations state that “treatment</text>
<text top="590" left="318" width="239" height="9" font="font6" id="p1_t110" reading_order_no="107" segment_no="11" tag_type="text">with alemtuzumab is a reasonable option for patients</text>
<text top="600" left="318" width="239" height="9" font="font6" id="p1_t111" reading_order_no="108" segment_no="11" tag_type="text">with progressive and symptomatic CLL that is refrac-</text>
<text top="612" left="318" width="239" height="9" font="font6" id="p1_t112" reading_order_no="109" segment_no="11" tag_type="text">tory to both alkylator-based and fludarabine-based</text>
<text top="623" left="318" width="239" height="9" font="font6" id="p1_t113" reading_order_no="110" segment_no="11" tag_type="text">regimens.” To account for the continued concern</text>
<text top="633" left="318" width="239" height="9" font="font6" id="p1_t114" reading_order_no="111" segment_no="11" tag_type="text">about the level of evidence supporting this recom-</text>
<text top="645" left="318" width="239" height="9" font="font6" id="p1_t115" reading_order_no="112" segment_no="11" tag_type="text">mendation and the potential risk–benefit profile of</text>
<text top="656" left="318" width="239" height="9" font="font6" id="p1_t116" reading_order_no="113" segment_no="11" tag_type="text">the therapy, a detailed set of qualifying statements</text>
<text top="666" left="318" width="93" height="9" font="font6" id="p1_t117" reading_order_no="114" segment_no="11" tag_type="text">was also developed.</text>
<text top="688" left="318" width="122" height="10" font="font8" id="p1_t118" reading_order_no="115" segment_no="16" tag_type="title">6. EXTERNAL REVIEW</text>
<text top="711" left="318" width="239" height="9" font="font6" id="p1_t119" reading_order_no="116" segment_no="17" tag_type="text">The systematic review and practice guideline recom-</text>
<text top="722" left="318" width="239" height="9" font="font6" id="p1_t120" reading_order_no="117" segment_no="17" tag_type="text">mendations were distributed to practitioners in On-</text>
</page>
</pdf2xml>
